Core Topics > Treatment, Recovery and Rehabilitation

RCT of Dexamphetamine maint. for the treatment of Methamphetamine dependence

(1/1)

Chip:
source: https://www.tni.org/files/publication-downloads/randomized-trial-dexamphetamine.pdf

Note: these are just excerpts only. Take the source pink for the full article. I have been trying to find someone to prescribe me Dex. for my ADHD (I was on it years ago and have since been buying therapeutic doses on the street for a little less than 20 years) so I don't have to self medicate with Meth.

Randomized controlled trial of Dexamphetamine maintenance for the treatment of Methamphetamine dependence

ABSTRACT

Aim To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexamphetamine in people dependent on methamphetamine. Design Randomized, double-blind, placebo-controlled trial.

Participants Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia
(DASSA) clinics. Intervention Participants were assigned randomly to receive up to 110 mg/day sustainedrelease dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks.

Medication was taken daily under pharmacist supervision.

Measurements Primary outcome measures included treatment retention, measures of methamphetamine consumption (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry.
 
Findings Treatment retention was significantly different between groups, with those who received dexamphetamine
remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014).

There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086).
Based on hair analysis, there was a significant decrease in methamphetamine concentration for both groups (P < 0.0001).

At follow-up, degree of methamphetamine dependence was significantly lower in the dexamphetamine group
(P = 0.042). Dexamphetamine maintenance was not associated with serious adverse events.

Conclusions: The results of this preliminary study have demonstrated that a maintenance pharmacotherapy programme of daily sustained release amphetamine dispensing under pharmacist supervision is both feasible and safe. The increased retention in the dexamphetamine group, together with the general decreases in methamphetamine use, degree of dependence and withdrawal symptom severity, provide preliminary evidence that this may be an efficacious treatment option for methamphetamine dependence.

FINAL CONCLUSIONS

This preliminary study evaluated the efficacy and safety of once-daily sustained-release dexamphetamine administered under supervision using a double-blind, placebocontrolled design. Participants in the dexamphetamine group remained in treatment significantly longer and had a significantly lower degree of methamphetamine dependence at follow-up. A significant difference in methamphetamine use between groups was not demonstrated.

This trial has shown the feasibility of implementing a supervised maintenance pharmacotherapy programme
for methamphetamine users that is acceptable to both clients and clinicians. The results of this study support
further investigation of maintenance pharmacotherapy as an intervention for methamphetamine dependence.

Navigation

[0] Message Index

It appears that you have not registered with dopetalk. To register, please click here...